Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097264 | 0.90 | LMNA (0.51) | LMNAMAPTALDH1A1NPC1HTT | |
| SCHEMBL25321827 | 0.86 | HTR2C (0.56) | LMNAMAPTALDH1A1HTR2CDRD4 | |
| SCHEMBL30475931 | 0.86 | HTR2C (0.56) | LMNAMAPTALDH1A1HTR2CDRD4 | |
| SCHEMBL20874120 | 0.86 | ALDH1A1 (0.54) | LMNAMAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL395684 | 0.83 | MAPT (0.49) | LMNAMAPTALDH1A1NPC1HTT | |
| SCHEMBL29985319 | 0.83 | MAPT (0.49) | LMNAMAPTALDH1A1NPC1HTT | |
| SCHEMBL615623 | 0.81 | NOTUM (0.61) | LMNAMAPTHTR2CDRD4NPC1 | |
| SCHEMBL27888907 | 0.81 | HTR2C (0.58) | LMNAMAPTALDH1A1HTR2CDRD4 | |
| SCHEMBL2306719 | 0.81 | ALDH1A1 (0.62) | LMNAMAPTALDH1A1NPC1DRD2 | |
| SCHEMBL3899182 | 0.80 | ESR2 (0.61) | GPR119DRD2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-4392423-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | Arthrosi Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028054-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-103153995-B | Condensed heterocyclic compouds as phosphodiesterase (PDES) inhibitor | 武田药品工业株式会社 | 2016-08-10 | — | — | CN | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| WO-2008113760-A2 | ARYLSULPHONYGLYCINE DERIVATIVES AS SUPPRESSORS OF THE INTERACTION OF GLYCOGEN PHOSPHORYLASE A WITH THE GL SUBUNIT OF GLYCOGEN-ASSOCIATED PROTEIN PHOSPHATASE 1 (PPL) FOR THE TREATMENT OF METABOLIC DISORDERS, PARTICULARY DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008094909-A2 | QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-07 | — | — | WO | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| CN-1976938-A | Thienopyrazole derivatives having PDE7 inhibitory activity | ASUBIO PHARMA CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1383760-A1 | BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002090347-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | LMNA 4778/4885MAPT 3836/4885ALDH1A1 1856/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | LMNA 2488/4885MAPT 4312/4885ALDH1A1 2795/4885 |
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | LMNA 956/4885MAPT 4047/4885ALDH1A1 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.